⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMPH News
Amphastar Pharmaceuticals, Inc.
Amorphical Announces Positive Final Long-Term Results from Phase 2 Crohn's Disease Trial: Results Confirm Efficacy and Show Sustained Clinical Remission
prnewswire.com
AMPH
Global Polymer-Based Solubility Enhancement Excipients Market Forecast 2031: Strong CAGR of 13.1% Fueled by Pharmaceutical Innovation | Valuates Reports
prnewswire.com
AMPH
CRDF
LLY
MRK
PFE
REGN
XBI
Amphastar Announces FDA Approval for Teriparatide Injection
accessnewswire.com
AMPH
Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications
accessnewswire.com
AMPH
Survey: 65 Percent of Pharma Marketers Distrust AI for Creating Regulatory Compliance Submissions
businesswire.com
KLICK
AMPH
Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients
prnewswire.com
AMPH
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
accessnewswire.com
AMPH
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
accessnewswire.com
AMPH
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
accessnewswire.com
AMPH
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
accessnewswire.com
AMPH